Clearance of pediatric actinic prurigo with dupilumab.

Actinic prurigo is a rare, idiopathic chronic photodermatosis of childhood characterized by excoriated papules, nodules, and plaques in sun-exposed areas. It is notoriously difficult to treat. The disorder involves a type IV hypersensitivity reaction driven by both Th1 and Th2 inflammatory pathways, the latter of which leads to secretion of IL-4, IL-5, IL-13, and production of B cells, IgE, and IgG4. Dupilumab, an IL-4 receptor antagonist, disrupts the Th2 pathway. We present a pediatric patient with severe, recalcitrant actinic prurigo who achieved rapid and sustained clearance with dupilumab. © 2020 Wiley Periodicals LLC.

Citation

Joshua B Eickstaedt, Samuel Starke, Dan Krakora, Molly Hinshaw, Lisa M Arkin. Clearance of pediatric actinic prurigo with dupilumab. Pediatric dermatology. 2020 Nov;37(6):1176-1178

Mesh Tags

Substances

PMID: 32869345

search → result